Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2006)
36 slides from Starpharma's shareholder meeting presentation, Nov 15, 2006
Slide 1: AGM - Chairman's and CEO's presentations
AGM - Chairman’s and CEO’s presentations Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY), to be held at 4.00pm today. An audio broadcast of the presentations may be heard from 4.30pm today on
Slide 2: For further information
Genital herpes: A recurrent, lifelong viral infection caused by the sexually transmitted herpes simplex virus type- 2 (HSV-2). It is one of the most prevalent STIs, estimated to infect between 15% and 25% of male and female adults in developed countries. This figure is expected to rise to about 39%
Slide 3: Chairman's Address
Chairman’s Address Annual General Meeting of Starpharma Holdings Limited, 15 November, 2006 Welcome to the Starpharma AGM for fiscal year 2005-2006. When I was asked to give a talk on leadership a few years ago, one theme that I developed at the time was the ability of leaders to use change to their
Slide 4: Chairman's Address (continued)
We have previously foreshadowed a desire of adding a US based director to the board, and following the acquisition of DNT we’ve invited the former CEO of a major US corporate to become a director of Starpharma. We expect to be able to make an announcement confirming that appointment in the near futu
Slide 5: Chairman's Address (continued)
VivaGel is the first microbicide to have received NIH funding for development against herpes and we are reasonably sure that it is the first microbicide with FDA investigational new drug status for prevention of herpes. There is plenty of good news and also plenty of hard work ahead for the Board an
Slide 6: Starpharma Holdings Limited
Starpharma Holdings Limited ASX:SPL USOTC:SPHRY AGM Presentation 15 November 2006 Dr Jackie Fairley – CEO
Slide 7: Forward-looking statements
This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual res
Slide 8: Outline
Outline 1. Key Achievements 2. Company Overview 3. VivaGelTM 4. DNT Acquisition 5. Pipeline 6. Conclusion 3
Slide 9: Key Achievements
1. KeyAchievements @ starpharma
Slide 10: Key Achievements
Key Achievements 9 HIV Funded: US$20.3M NIH funds VivaGel™ HIV development with non-dilutive funding 9 Genital Herpes Funded NIH funds VivaGel™ Genital Herpes Development 9 HIV Fast Tracked US regulator FDA designates VivaGel™ a fast track product 9 Herpes IND Cleared FDA clears VivaGel™ Genital Her
Slide 11: Company Overview
2. Company Overview @ starpharma
Slide 12: Company Overview
Company Overview World leader in the development of dendrimer Starpharma Holdings Limited nanotechnology products for pharmaceutical and life- ASX Code SPL sciences Level 1 ADR Code SPHRY Lead product VivaGel™ is being developed (under Share Price (14/11/06) 51 c 12 Month High/Low 64 c / 35 c IN
Slide 13: Company Structure
Company Structure Starpharma Holdings 8.6% Limited ASX:SPL USOTC:SPHRY 100.0% 100.0% Dendritic Nanotechnologies Starpharma Pty Ltd Inc. (DNT) 36 employees based in Melbourne, Australia 16 employees based in Michigan, USA Uses dendrimer technology to discover, Leading developer and provider o
Slide 14: Financial Snapshot
Financial Snapshot Starpharma is in a strong financial position: – A$13.3M in cash at Oct 06 (A$14.3M – Loss for 05/06 down 3% to A$7.5M Jun 06) – Revenue1 A$7.0M in 05/06, a A$5M increase – 12 month burn to Oct 06 of A$6.6M over 04/05 (A$8.2M 05/06) – NIH and P3 Funding > A$30M 1 Post DNT transac
Slide 15: ADR Program and US Shareholding
ADR Program and US Shareholding Starparma’s ADR program has been extremely successful since launch in January 2005 ADR Uptake – Growth of 137% in ADRs issued in the past 12 months Shares 12% issued to – Average monthly growth of 7% DNT holders Traded by major brokers including Merrill Lynch, 10%
Slide 16: Enhanced Pipeline: Balanced for Risk
Enhanced Pipeline: Balanced for Risk Proof of Pharmaceutical & Medical Products Concept Lead Clinical Trials Sales VivaGel™ ► HSV-2 prevention ► HIV prevention ► condoms coating & other line extensions ADME Engineering™ ► Therapeutic protein PK optimisation Drug Delivery - Small Molecules ► Cancer t
Slide 17: VivaGel
3. VivaGel™ VivaGelTM packaged into pre-filled applicators.
Slide 18: VivaGel - Lead Product for Prevention of STIs
VivaGelTM – Lead Product for Prevention of STIs VivaGelTM is a vaginal microbicide being HIV developed to prevent sexually transmitted Major health burden in both developed and developing countries infections in women 39 million people living with HIV; every – Currently being developed under t
Slide 19: VivaGel - Significant Achievements
VivaGelTM – Significant Achievements Successfully completed Phase 1 trial in Humans Nov 04 Receives A$26M non-dilutive NIH funding for development in HIV Oct 05 (without downstream commercial obligations) Jan 06 Granted FDA Fast Track Status for HIV 2004 2005 2006 Apr 06 The only microbicide
Slide 20: VivaGel Market Update
VivaGel™ Market Update Two clinical trials underway in the USA and Australia (Kenyan site to commence shortly) Good progress with Scale-up and toxicology programs Due to HIV Microbicide trial issues with recruitment, and retention in trials VivaGel™ regulatory approval milestone revised from 2
Slide 21: Commercial Opportunity for Microbicides
Commercial Opportunity for Microbicides Large, addressable markets Estimated Market for microbicides in Developed Countries – HIV primarily in developing countries Market Average Frequency of Use Per Annum – HSV-2 in both developing and developed countries Penetration 25x 50x 100x US$M US$M US$M
Slide 22: DNT Acquisition
4. DNT Acquisition DENDRITIC NANOTECHNOLOGIES INC
Slide 23: Significant Acquisition Benefits
Significant Acquisition Benefits Marketed products, near-term revenues 1. Diversified Product Portfolio Diversified risk: pharma, life-science and industrial Optimal leverage of internal resources including 2. Significant Development and commercial, regulatory, scale-up and discovery Commercia
Slide 24: Enhanced Portfolio
Enhanced Portfolio Multiple Near-Term Future High-Value Commercial Commercial Opportunities Opportunities Industrial Products Life-science Applications Pharmaceutical Products Research Research Drug Drug VivaGel™ VivaGel™ Reagents Reagents Optimisation Optimisation Industrial Industrial Medical Medi
Slide 25: Pipeline
5. Pipeline a® we ee @ starpharma
Slide 26: Enhanced Pipeline: Balanced for Risk
Enhanced Pipeline: Balanced for Risk Proof of Pharmaceutical & Medical Products Concept Lead Clinical Trials Sales VivaGel™ ► HSV-2 prevention ► HIV prevention ► condoms coating & other line extensions ADME Engineering™ ► Therapeutic protein PK optimisation Drug Delivery - Small Molecules ► Cancer t
Slide 27: Pipeline: Enhanced Near Term Opportunities
Pipeline: Enhanced Near Term Opportunities Marketed Dendrimer PrioFect™ siRNA transfection Materials Science / Products agents Industrial Applications Existing product sales Transfection reagent Sector Discussions with… Application and licensed dendrimer market: $120M growing Oil "Top 5" US Oil
Slide 28: Conclusion
6. Conclusion Xe) starpharma
Slide 29: Investment Highlights
Investment Highlights >US$26m* non-diluting funding from the NIH for VivaGel™; P3 funding from the Australian Government for lead development VivaGel™ - the only microbicide with NIH funding for genital herpes Significant commercial opportunities for microbicides Significant US shareholder b
Slide 30: New website in preparation
Preview: New website in preparation www.starpharma.com Further information: info@starpharma
Slide 31: Supplementary Material
@ starpharma Supplementary Material @ starp Larma
Slide 32: Dendrimer Technology: Overview
Dendrimer Technology: Overview Unique Characteristics of Dendrimers Commercial Applications of Dendrimers Precisely defined, synthetic macromolecules Key enabling nanoscale technology Precisely defined surface topology Diverse range of pharma, diagnostic & materials applications Can be des
Slide 33: VivaGel - Product Features and Performance
VivaGelTM – Product Features and Performance Market research indicates microbicide gels will have good uptake Product Offers Female controlled, discreet and convenient Several Key Compelling competitive advantages: efficacy; non-irritant; broad Advantages activity Contraceptive activity (in
Slide 34: VivaGel - Significant Advantages Over Competitors
VivaGelTM – Significant Advantages Over Competitors Competitor Category Key Disadvantages VivaGelTM Advantages VivaGel™ is the only microbicide with an FDA IND for genital HSV -2 herpes Ulceration possible; potential No surfactant properties; Surfactants/ Detergents incr. risk of HIV infection n
Slide 35: Pipeline Management
Pipeline Management Development approach Starpharma StarpharmaProduct Product Starpharma Starpharma Development Development resource resource Mitigated by external demand demand funding sources, e.g. e.g.VivaGel™, VivaGel™, e.g. NIH High High PrioFect™ PrioFect™ Partnered Partneredjoint joint Starph
Slide 36: Partners
Partners Industry Collaborators Research/Uni. Collaborators 31
Starpharma Holdings — Shareholder Meeting (November 2006) on 6ix